Board Meeting Details

The Board of Directors meeting was held on Wednesday, 11th November 2026 at the registered office of the company in Hyderabad. The meeting commenced at 5:00 PM and concluded at 5:43 PM.

Key Decisions Approved

1. Financial Results Approval

  • Approved the Standalone unaudited Financial Results of the company for the quarter and half year ended on 30th September, 2026
  • Limited Review Report thereon was also approved

2. Corporate Office Relocation

  • Approved opening of Corporate Office at "Flat No-308B, 3rd floor, Block B, 'The Platina' Kondapur Road, Gachibowli, Hyderabad, Serilingampally, Ranga Reddy, Telangana, India, 500032"
  • Effective from 16th November, 2026

3. Books of Accounts Maintenance

  • Approved maintenance of books of accounts at the new corporate office address (same as above)
  • Effective from 16th November, 2026
  • This is a place other than the Registered Office of the Company

4. Change in Director Designation

  • Based on letter received from Mr. Venkateshwarlu Pulluru
  • Approved change in designation from Whole time Director to Non-Executive Non-Independent Director
  • Effective from closing of business hours of 11th November, 2026

Financial Results Summary (Quarter Ended 30th September 2026)

Income Statement Highlights (₹ in Lakhs):

  • Revenue from Operations (Net): ₹4,473.12 (Q2 FY27) vs ₹3,635.89 (Q2 FY26) - 23% increase YoY
  • Total Income: ₹4,473.12 (Q2 FY27) vs ₹3,639.14 (Q2 FY26)
  • Purchase of stock-in-trade: ₹4,594.11 (Q2 FY27) vs ₹3,668.48 (Q2 FY26)
  • Employee benefits expense: ₹18.77 (Q2 FY27) vs ₹14.18 (Q2 FY26)
  • Finance cost: ₹12.98 (Q2 FY27)
  • Depreciation and amortization: ₹12.85 (Q2 FY27) vs ₹1.38 (Q2 FY26)
  • Profit before tax: ₹186.62 (Q2 FY27) vs ₹71.89 (Q2 FY26) - 160% increase YoY
  • Tax expense: ₹30.30 (Q2 FY27) vs ₹18.58 (Q2 FY26)
  • Net profit: ₹156.32 (Q2 FY27) vs ₹53.31 (Q2 FY26) - 193% increase YoY

Half Year Results (6 months ended 30th September 2026):

  • Revenue from Operations (Net): ₹8,164.51 (H1 FY27) vs ₹5,871.01 (H1 FY26)
  • Net profit: ₹274.21 (H1 FY27) vs ₹64.03 (H1 FY26)

Earnings Per Share (EPS):

  • Basic EPS: ₹0.57 for Q2 FY27 (₹0.37 for Q2 FY26)
  • Diluted EPS: ₹0.57 for Q2 FY27 (₹0.49 for Q2 FY26)
  • Basic EPS: ₹0.96 for H1 FY27 (₹0.44 for H1 FY26)

Capital Structure:

  • Paid-up equity share capital: ₹2,847.00 lakhs (Face Value: ₹10 per share)
  • Previous periods: ₹2,389.50 lakhs (Q1 FY27), ₹1,448.00 lakhs (Q2 FY26), ₹1,993.50 lakhs (FY26)

Balance Sheet Position (as at 30th September 2026)

Assets (₹ in Lakhs):

  • Total Assets: ₹14,331.74 (Unaudited) vs ₹9,242.32 (Audited as at 31st March 2026)
  • Non-current assets: ₹766.85 (Property, plant and equipment: ₹296.01, Right to use assets: ₹18.81, Intangible assets: ₹404.00, Loans: ₹4.32, Deferred tax assets: ₹43.71)
  • Current assets: ₹13,564.89 (Inventories: ₹1,527.11, Trade receivables: ₹10,574.03, Cash and cash equivalents: ₹321.45, Loans: ₹863.06, Other current assets: ₹279.24)

Liabilities and Equity (₹ in Lakhs):

  • Total Equity: ₹6,534.79 (Share capital: ₹2,847.00, Other equity: ₹3,687.79)
  • Non-current liabilities: ₹652.62 (Long-term borrowings)
  • Current liabilities: ₹7,144.33 (Trade payables: ₹6,930.05, Other financial liabilities: ₹5.44, Provisions: ₹208.17, Other current liabilities: ₹0.67)

Cash Flow Statement (for period ended 30th September 2026)

Cash Flow (₹ in Lakhs):

  • Net cash used in operating activities: ₹(1,366.50)
  • Net cash used in investing activities: ₹(296.93)
  • Net cash from financing activities: ₹1,689.02
  • Net increase in cash: ₹25.59
  • Cash and cash equivalents opening: ₹295.86
  • Cash and cash equivalents closing: ₹321.45

Additional Information

Business Segment: The Company has only one business segment 'Manufacturing and Trading of all kind of active Pharmaceutical Ingredients (Bulk Drugs)'.

Name Change: The Company was formerly known as TRIMURTHI LIMITED. The name was changed due to change in business activity.

Subsidiaries: The company has no Subsidiary, Associate or Joint Venture company(ies) as on September 30, 2026.

Regulatory Compliance: The financial results have been prepared in accordance with Indian Accounting Standards ('IND AS') and Regulation 33 of the SEBI (Listing Obligations & Disclosure Requirements) Regulation 2015.

Limited Review: The financial results were reviewed by CVS Balachandra Rao & Co., Chartered Accountants, who issued a limited review report stating nothing has come to their attention that causes them to believe the results contain any material misstatement.

Director Redesignation Details:

  • Reason for change: Based on personal request letter from Mr. Venkateshwarlu Pulluru
  • Effective date: 11th November, 2026
  • Previous designation: Whole-time Director
  • New designation: Non-Executive Non-Independent Director
  • Profile details: Not provided in the disclosure
  • Relationship between directors: Nil

Website Disclosure: The standalone results of the company are available on the company's website https://novelixpharma.com/